Related Experiment Video
Updated: May 4, 2026
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase
Linh C Bui1, Laure Tabouy1, Florent Busi1
1Unit of Functional and Adaptative Biology (BFA), Université Paris Diderot, Sorbonne Paris Cité, CNRS UMR 8251, 75013 Paris, France.
Abstract:
Down syndrome is the most common aneuploidy. It is caused by the presence of an extra copy of chromosome 21. Several studies indicate that aberrant expression of the kinase Dyrk1a (dual-specificity tyrosine phosphorylation-regulated kinase 1a) is implicated in Down syndrome, in particular in the onset of mental retardation. Moreover, elevated Dyrk1a activity may also be a risk factor for other neurodegenerative disorders such as Alzheimer's disease. Over the past years, Dyrk1a has appeared as a potential drug target. Availability of sensitive and quantitative enzyme assays is of prime importance to understand the role of Dyrk1a and to develop specific inhibitors. Here, we describe a new method to measure Dyrk1a activity based on the separation and quantification of specific fluorescent peptides (substrate and phosphorylated product) by high-performance liquid chromatography (HPLC). Kinetic and mechanistic analyses using well-known inhibitors of Dyrk1a confirmed the reliability of this approach. In addition, this assay was further validated using brain extracts of mice models expressing different copies of the Dyrk1a gene. Our results indicate that this novel Dyrk1a assay is simple, sensitive, and specific. It avoids the use of radioactivity-based approaches that, until now, have been widely employed to measure Dyrk1a activity.
Insights
A new high-performance liquid chromatography (HPLC) assay quantifies dual-specificity tyrosine phosphorylation-regulated kinase 1a (Dyrk1a) activity. This sensitive method aids research into Down syndrome and neurodegenerative diseases by offering a non-radioactive alternative.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- Down syndrome, the most common aneuploidy, is linked to aberrant expression of the dual-specificity tyrosine phosphorylation-regulated kinase 1a (Dyrk1a).
- Elevated Dyrk1a activity is implicated in Down syndrome-associated intellectual disability and may contribute to neurodegenerative disorders like Alzheimer's disease.
- Dyrk1a is a recognized drug target, necessitating precise enzyme activity assays for inhibitor development and mechanistic studies.
Purpose of the Study:
- To develop and validate a novel, sensitive, and quantitative assay for measuring Dyrk1a enzyme activity.
- To provide a non-radioactive alternative to existing methods for Dyrk1a activity assessment.
- To facilitate research on the role of Dyrk1a in Down syndrome and other neurodegenerative conditions.
Main Methods:
- A new assay was established utilizing high-performance liquid chromatography (HPLC) for the separation and quantification of fluorescently labeled substrate and phosphorylated product.
- The assay's reliability was confirmed through kinetic and mechanistic analyses with known Dyrk1a inhibitors.
- Validation was performed using brain extracts from mouse models with varying Dyrk1a gene copy numbers.
Main Results:
- The developed HPLC-based assay accurately measures Dyrk1a activity.
- The assay demonstrated simplicity, sensitivity, and specificity.
- This method successfully avoids the use of radioactivity, offering a safer and potentially more accessible alternative.
Conclusions:
- A novel, non-radioactive HPLC assay for Dyrk1a activity has been successfully developed and validated.
- This assay is suitable for kinetic studies, inhibitor screening, and analysis of biological samples.
- The assay provides a valuable tool for advancing research into Dyrk1a's role in Down syndrome and neurodegenerative diseases.
